Diatrizoic Acid

Diatrizoic Acid

SCHEMBL468613

CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[NaH]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TACR1TTRgyrAgyrBparCparE

The experimentally established mechanism targets of Diatrizoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.97
KDM4E B2RXH2 2/20 0.47
LMNA P02545 3/20 0.47
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
HIF1A Q16665 1/20 0.33
PDE4A P27815 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diatrizoic Acid SCHEMBL720469 0.99 SMN1; SMN2 (1.00) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Diatrizoic Acid SCHEMBL1685085 0.99 SMN1; SMN2 (1.00) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Diatrizoic Acid SCHEMBL107036 0.99 SMN1; SMN2 (1.00) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Diatrizoic Acid SCHEMBL2501947 0.97 SMN1; SMN2 (0.97) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Iothalamic Acid SCHEMBL3060866 0.92 SMN1; SMN2 (0.83) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Diatrizoic Acid SCHEMBL4334352 0.92 SMN1; SMN2 (0.87) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Iothalamic Acid SCHEMBL29488709 0.91 SMN1; SMN2 (0.84) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Iothalamic Acid SCHEMBL180546 0.91 SMN1; SMN2 (0.84) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Iothalamic Acid SCHEMBL48785 0.91 SMN1; SMN2 (0.84) SMN1; SMN2KDM4ELMNACYP1A2TSHR
Iodamide SCHEMBL9808844 0.89 SMN1; SMN2 (0.78) SMN1; SMN2KDM4ELMNACYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114739966-A Tumor screening kit based on blood analysis 上海翊嘉生物科技有限公司 2022-07-12 CN claimed
JP-7309782-A None JP disclosed
US-20250058078-A1 DIAGNOSTIC CATHETERS, GUIDE CATHETERS, VISUALIZATION DEVICES AND CHORD MANIPULATION DEVICES, AND RELATED KITS AND METHODS ANCORA HEART, INC. 2025-02-20 US disclosed
US-11980722-B2 Diagnostic catheters, guide catheters, visualization devices and chord manipulation devices, and related kits and methods ANCORA HEART, INC. (US) 2024-05-14 US disclosed
CN-114739966-A Tumor screening kit based on blood analysis 上海翊嘉生物科技有限公司 2022-07-12 CN disclosed
US-20220152348-A1 DIAGNOSTIC CATHETERS, GUIDE CATHETERS, VISUALIZATION DEVICES AND CHORD MANIPULATION DEVICES, AND RELATED KITS AND METHODS ANCORA HEART, INC. 2022-05-19 US disclosed
US-11202883-B2 Diagnostic catheters, guide catheters, visualization devices and chord manipulation devices, and related kits and methods ANCORA HEART, INC. (US) 2021-12-21 US disclosed
WO-2021162110-A1 GEL DOSIMETER FOR MEASURING RADIATION DOSES 学校法人北里研究所 2021-08-19 WO disclosed
US-20200147343-A1 DIAGNOSTIC CATHETERS, GUIDE CATHETERS, VISUALIZATION DEVICES AND CHORD MANIPULATION DEVICES, AND RELATED KITS AND METHODS GUIDED DELIVERY SYSTEMS INC. 2020-05-14 US disclosed
US-10625046-B2 Diagnostic catheters, guide catheters, visualization devices and chord manipulation devices, and related kits and methods ANCORA HEART, INC. (US) 2020-04-21 US disclosed
WO-2008057534-A2 METHODS AND COMPOSITIONS FOR ORGAN PROTECTION UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) 2008-05-15 WO disclosed
WO-2007127958-A2 DETECTION AND IMAGING OF TARGET TISSUE BARNES-JEWISH HOSPITAL (US) 2007-11-08 WO disclosed
US-20070258908-A1 Detection and imaging of target tissue KEREOS, INC. 2007-11-08 US disclosed
EP-1776118-A2 IRON CHELATORS FOR TREATING RADIOCONTRAST-ASSOCIATED RENAL DYSFUNCTION Shiva Biomedical, LLC (US) 2007-04-25 EP disclosed
US-20060127315-A1 Methods of treating humans undergoing injection of a contrast agent SHIVA BIOMEDICAL, L.L.C. (US) 2006-06-15 US disclosed
WO-2006017650-A2 IRON CHELATORS FOR TREATING RADIOCONTRAST-ASSOCIATED RENAL DYSFUNCTION SHIVA BIOMEDICAL, LLC (US) 2006-02-16 WO disclosed
JP-H07309782-A CONTRAST MEDIUM OGAWA TAKAHIRO 1995-11-28 JP disclosed
US-5346696-A Recombinent Interferon KOREA GREEN CROSS CORPORATION (KR) 1994-09-13 US disclosed
EP-0544878-A1 ASIALOGLYCOPROTEIN-CONJUGATED MEDICINAL AGENT COREA GREEN CROSS CORPORATION (KR) 1993-06-09 EP disclosed
WO-1992022310-A1 ASIALOGLYCOPROTEIN-CONJUGATED MEDICINAL AGENT LIVER RESEARCH FOUNDATION OF KOREA (KR) 1992-12-23 WO disclosed